Plus Therapeutics Secures Agreement With Telix IsoTherapeutics For Radioisotope Supply

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company specialising in radiotherapeutics, announced the extension of its Master Services Agreement (MSA) with Telix IsoTherapeutics Group Inc., a subsidiary of the Telix Group. This agreement ensures a consistent supply of cGMP Re-186, the primary radioisotope in Plus Therapeutics’ lead radiotherapeutic candidate, Rhenium (186Re) Obisbemeda.

Marc H. Hedrick, M.D., Plus Therapeutics’ President and Chief Executive Officer, commented, “This continuing agreement with Telix IsoTherapeutics Group builds on our recently announced partnership with SpectronRx and reflects our comprehensive supply chain strategy. By securing the supply of Re-186 through IsoTherapeutics and leveraging SpectronRx for final drug manufacturing of Rhenium (186Re) Obisbemeda, we are establishing a scalable, end-to-end supply chain that positions us to meet the demands of late-stage clinical trials and future commercial needs.”

Key Highlights:

• It focuses on producing the essential radionuclide intermediate, aluminium perrhenate, and completing cGMP Re-186 processing.

• Supports expanded, scalable, and on-demand manufacturing to strengthen the supply chain.